Top

Published in:

01-01-2008

Anemia and Transfusions in Patients Undergoing Surgery for Cancer

Authors: Randal S. Weber, MD, FACS, Nicolas Jabbour, MD, FACS, Robert C. G. Martin II, MD, FACS

Published in: Annals of Surgical Oncology | Issue 1/2008

Abstract

Preoperative, operative, and postoperative factors may all contribute to high rates of anemia in patients undergoing surgery for cancer. Allogeneic blood transfusion is associated with both infectious risks and noninfectious risks such as human errors, hemolytic reactions, transfusion-related acute lung injury, transfusion-associated graft-versus-host disease, and transfusion-related immune modulation. Blood transfusion may also be associated with increased risk of cancer recurrence. Blood-conservation measures such as preoperative autologous donation, acute normovolemic hemodilution, perioperative blood salvage, recombinant human erythropoietin (epoetin alfa), electrosurgical dissection, and minimally invasive surgical procedures may reduce the need for allogeneic blood transfusion in elective surgery. This review summarizes published evidence of the consequences of anemia and blood transfusion, the effects of blood storage, the infectious and noninfectious risks of blood transfusion, and the role of blood-conservation strategies for cancer patients who undergo surgery. The optimal blood-management strategy remains to be defined by additional clinical studies. Until that evidence becomes available, the clinical utility of blood conservation should be assessed for each patient individually as a component of preoperative planning in surgical oncology.

Krupp NL, Weinstein G, Chalian A, Berlin JA, Wolf P, Weber RS. Validation of a transfusion prediction model in head and neck cancer surgery. Arch Otolaryngol Head Neck Surg 2003; 129:1297–302PubMedCrossRef

Shvarts O, Tsui KH, Smith RB, Kernion JB, Belldegrun A. Blood loss and the need for transfusion in patients who undergo partial or radical nephrectomy for renal cell carcinoma. J Urol 2000; 164:1160–3PubMedCrossRef

Benoist S, Panis Y, Pannegeon V, Alves A, Valleur P. Predictive factors for perioperative blood transfusions in rectal resection for cancer: A multivariate analysis of a group of 212 patients. Surgery 2001; 129:433–9PubMed

Elias D, Raynard B, Boige V, Laplanche A, Estphan G, Malka D, Pocard M. Impact of the extent and duration of cytoreductive surgery on postoperative hematological toxicity after intraperitoneal chemohyperthermia for peritoneal carcinomatosis. J Surg Oncol 2005; 90:220–5PubMedCrossRef

Dunne JR, Gannon CJ, Osborn TM, Taylor MD, Malone DL, Napolitano LM. Preoperative anemia in colon cancer: assessment of risk factors. Am Surg 2002; 68:582–7PubMed

Shander A, Knight K, Thurer R, Adamson J, Spence R. Prevalence, outcomes of anemia in surgery: a systematic review of the literature. Am J Med 2004; 116(Suppl 7A):58S–69SPubMedCrossRef

Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91:1616–34PubMedCrossRef

Birgegard G, Aapro MS, Bokemeyer C, et al. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology 2005; 68(Suppl 1):3–11PubMedCrossRef

Voelter V, Schuhmacher C, Busch R, Peschel C, Siewert JR, Lordick F. Incidence of anemia in patients receiving neoadjuvant chemotherapy for locally advanced esophagogastric cancer. Ann Thorac Surg 2004; 78:1037–41PubMedCrossRef

10.

Monk TG, Goodnough LT, Brecher ME, Colberg JW, Andriole GL, Catalona WJ. A prospective randomized comparison of three blood conservation strategies for radical prostatectomy. Anesthesiology 1999; 91:24–33PubMedCrossRef

11.

Lent V, Neuss A. Management of bleeding, transfusion requirement and removal of catheters in transurethral prostate resection. Eur Urol 1997; 32:257–67PubMed

12.

Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001; 91:2214–21PubMedCrossRef

13.

Lutterbach J, Guttenberger R. Anemia is associated with decreased local control of surgically treated squamous cell carcinomas of the glottic larynx. Int J Radiat Oncol Biol Phys 2000; 48:1345–50PubMed

14.

Martin-Loeches M, Orti RM, Asins E, Llixiona J. The prognostic implications of anaemia in the outcome of patients with early stages of uterine cervix carcinoma. Arch Gynecol Obstet 2003; 267:121–5PubMedCrossRef

15.

Macdonald G, Hurman DC. Influence of anaemia in patients with head and neck cancer receiving adjuvant postoperative radiotherapy in the Grampian region. Clin Oncol (R Coll Radiol) 2004; 16:63–70

16.

Yovino S, Kwok Y, Krasna M, Bangalore M, Suntharalingam M. An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone. Int J Radiat Oncol Biol Phys 2005; 62:1438–43PubMed

17.

Saibishkumar EP, Patel FD, Ghoshal S, Kumar V, Karunanidhi G, Sharma SC. Results of salvage radiotherapy after inadequate surgery in invasive cervical carcinoma patients: a retrospective analysis. Int J Radiat Oncol Biol Phys 2005; 63:828–33PubMed

18.

van de Pol SM, Doornaert PA, de Bree R, Leemans CR, Slotman BJ, Langendijk JA. The significance of anemia in squamous cell head and neck cancer treated with surgery and postoperative radiotherapy. Oral Oncol 2006; 42:131–8PubMedCrossRef

19.

Cella D. Quality of life and clinical decisions in chemotherapy-induced anemia. Oncology (Williston Park) 2006; 20:25–8

20.

Blohmer JU, Dunst J, Harrison L, et al. Cancer-related anemia: biological findings, clinical implications and impact on quality of life. Oncology 2005; 68(Suppl 1):12–21PubMedCrossRef

21.

Dougenis D, Patrinou V, Filos KS, Theodori E, Vagianos K, Maniati A. Blood use in lung resection for carcinoma: perioperative elective anaemia does not compromise the early outcome. Eur J Cardiothorac Surg 2001; 20:372–7PubMedCrossRef

22.

Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340:409–17PubMedCrossRef

23.

Carson JL, Terrin ML, Barton FB, et al. A pilot randomized trial comparing symptomatic vs. hemoglobin-level-driven red blood cell transfusions following hip fracture. Transfusion 1998; 38:522–9PubMedCrossRef

24.

Bush RL, Pevec WC, Holcroft JW. A prospective, randomized trial limiting perioperative red blood cell transfusions in vascular patients. Am J Surg 1997; 174:143–8PubMedCrossRef

25.

Busch MP, Kleinman SH, Nemo GJ. Current and emerging infectious risks of blood transfusions. JAMA 2003; 289:959–62PubMedCrossRef

26.

Goodnough LT. Risks of blood transfusion. Crit Care Med 2003; 31:S678–86PubMedCrossRef

27.

Weusten JJ, van Drimmelen HA, Lelie PN. Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT. Transfusion 2002; 42:537–48PubMedCrossRef

28.

Soldan K, Barbara JA, Ramsay ME, Hall AJ. Estimation of the risk of hepatitis B virus, hepatitis C virus and human immunodeficiency virus infectious donations entering the blood supply in England, 1993–2001. Vox Sang 2003; 84:274–86PubMedCrossRef

29.

Seed CR, Kiely P, Keller AJ. Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus. Intern Med J 2005; 35:592–8PubMedCrossRef

30.

Kleinman S, Chan P, Robillard P. Risks associated with transfusion of cellular blood components in Canada. Transfus Med Rev 2003; 17:120–62PubMed

31.

O’Brien SF, Yi QL, Fan W, Scalia V, Kleinman SH, Vamvakas EC. Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services. Transfusion 2007; 47:316–25PubMedCrossRef

32.

Marcucci C, Madjdpour C, Spahn DR. Allogeneic blood transfusions: benefit, risks and clinical indications in countries with a low or high human development index. Br Med Bull 2004; 70:15–28PubMedCrossRef

33.

Cruz JR, Perez-Rosales MD, Zicker F, Schmunis GA. Safety of blood supply in the Caribbean countries: role of screening blood donors for markers of hepatitis B and C viruses. J Clin Virol 2005; 34 Suppl 2:S75–80PubMedCrossRef

34.

Imarengiaye CO, Enosolease ME, Iribhogbe PE, Ehigiegba AE. Risk of transfusion-transmitted hepatitis C virus in a tertiary hospital in Nigeria. Public Health 2006; 120:274–8PubMedCrossRef

35.

Llewelyn CA, Hewitt PE, Knight RS, Amar K, Cousens S, Mackenzie J, Will RG. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 2004; 363:417–21PubMedCrossRef

36.

Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 2004; 364:527–9PubMedCrossRef

37.

Wilson K, Ricketts MN. A third episode of transfusion-derived vCJD. Lancet 2006; 368:2037–9PubMedCrossRef

38.

Hewitt PE, Llewelyn CA, Mackenzie J, Will RG. Three reported cases of variant Creutzfeldt-Jakob disease transmission following transfusion of labile blood components. Vox Sang 2006; 91:348PubMedCrossRef

39.

Dellinger EP, Anaya DA. Infectious and immunologic consequences of blood transfusion. Crit Care 2004; 8(Suppl 2):S18–23PubMedCrossRef

40.

Montgomery SP, Brown JA, Kuehnert M, et al. Transfusion-associated transmission of West Nile virus, United States 2003 through 2005. Transfusion 2006; 46:2038–46PubMedCrossRef

41.

Madjdpour C, Heindl V, Spahn DR. Risks, benefits, alternatives and indications of allogenic blood transfusions. Minerva Anestesiol 2006; 72:283–98PubMed

42.

Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. First of two parts—blood transfusion. N Engl J Med 1999; 340:438–47PubMedCrossRef

43.

AuBuchon JP, Birkmeyer JD, Busch MP. Safety of the blood supply in the United States: opportunities and controversies. Ann Intern Med 1997; 127:904–9PubMed

44.

Brittenham GM, Klein HG, Kushner JP, Ajioka RS. Preserving the national blood supply. Hematology (Am Soc Hematol Educ Program) 2001:422–432

45.

Nuttall GA, Stehling LC, Beighley CM, Faust RJ. Current transfusion practices of members of the American Society of Anesthesiologists: a survey. Anesthesiology 2003; 99:1433–43PubMedCrossRef

46.

Stainsby D, Williamson L, Jones H, Cohen H. 6 Years of shot reporting–its influence on UK blood safety. Transfus Apher Sci 2004; 31:123–31PubMedCrossRef

47.

Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev 2006:CD005033

48.

Stainsby D. ABO incompatible transfusions—experience from the UK Serious Hazards of Transfusion (SHOT) scheme Transfusions ABO incompatible. Transfus Clin Biol 2005; 12:385–8PubMedCrossRef

49.

Williamson LM, Lowe S, Love EM, et al. Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports. BMJ 1999; 319:16–9PubMed

50.

Sazama K. Transfusion errors: scope of the problem, consequences, and solutions. Curr Hematol Rep 2003; 2:518–21PubMed

51.

Pagliaro P, Rebulla P. Transfusion recipient identification. Vox Sang 2006; 91:97–101PubMedCrossRef

52.

Baele PL, De Bruyere M, Deneys V, et al. Bedside transfusion errors. A prospective survey by the Belgium SAnGUIS Group. Vox Sang 1994; 66:117–21PubMedCrossRef

53.

Dzik WH. Technology for enhanced transfusion safety. Hematology Am Soc Hematol Educ Program 2005; 5:476–82

54.

Janatpour K, Holland PV. Noninfectious serious hazards of transfusion. Curr Hematol Rep 2002; 1:149–55PubMed

55.

Perrotta PL, Snyder EL. Non-infectious complications of transfusion therapy. Blood Rev 2001; 15:69–83PubMedCrossRef

56.

Moore SB. Transfusion-related acute lung injury (TRALI): clinical presentation, treatment, and prognosis. Crit Care Med 2006; 34:S114–7PubMedCrossRef

57.

Zoon KC. U.S. Food and Drug Administration Center for Biologics Evaluation and Research Alert: Transfusion Related Acute Lung Injury. Available at: http://www.fda.gov/cber/ltr/trali101901.htm. 2002

58.

Silliman CC, Boshkov LK, Mehdizadehkashi Z, et al. Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood 2003; 101:454–62PubMedCrossRef

59.

Kopko PM. Leukocyte antibodies and biologically active mediators in the pathogenesis of transfusion-related acute lung injury. Curr Hematol Rep 2004; 3:456–61PubMed

60.

Kopko PM, Marshall CS, MacKenzie MR, Holland PV, Popovsky MA. Transfusion-related acute lung injury: report of a clinical look-back investigation. JAMA 2002; 287:1968–71PubMedCrossRef

61.

Higgins MJ, Blackall DP. Transfusion-associated graft-versus-host disease: a serious residual risk of blood transfusion. Curr Hematol Rep 2005; 4:470–6PubMed

62.

Opelz G, Sengar DP, Mickey MR, Terasaki PI. Effect of blood transfusions on subsequent kidney transplants. Transplant Proc 1973; 5:253–9PubMed

63.

Vamvakas EC. WBC-containing allogeneic blood transfusion and mortality: a meta-analysis of randomized controlled trials. Transfusion 2003; 43:963–73PubMedCrossRef

64.

Fergusson D, Khanna MP, Tinmouth A, Hebert PC. Transfusion of leukoreduced red blood cells may decrease postoperative infections: two meta-analyses of randomized controlled trials. Can J Anaesth 2004; 51:417–24PubMed

65.

Chung M, Steinmetz OK, Gordon PH. Perioperative blood transfusion and outcome after resection for colorectal carcinoma. Br J Surg 1993; 80:427–32PubMedCrossRef

66.

Vamvakas EC, Blajchman MA. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood 2001; 97:1180–95PubMedCrossRef

67.

Tachibana M, Tabara H, Kotoh T, et al. Prognostic significance of perioperative blood transfusions in resectable thoracic esophageal cancer. Am J Gastroenterol 1999; 94:757–65PubMedCrossRef

68.

Asahara T, Katayama K, Itamoto T, et al. Perioperative blood transfusion as a prognostic indicator in patients with hepatocellular carcinoma. World J Surg 1999; 23:676–80PubMedCrossRef

69.

Makino Y, Yamanoi A, Kimoto T, El-Assal ON, Kohno H, Nagasue N. The influence of perioperative blood transfusion on intrahepatic recurrence after curative resection of hepatocellular carcinoma. Am J Gastroenterol 2000; 95:1294–300PubMedCrossRef

70.

Hyung WJ, Noh SH, Shin DW, Huh J, Huh BJ, Choi SH, Min JS. Adverse effects of perioperative transfusion on patients with stage III and IV gastric cancer. Ann Surg Oncol 2002; 9:5–12PubMedCrossRef

71.

Pysz M. Blood transfusions in breast cancer patients undergoing mastectomy: possible importance of timing. J Surg Oncol 2000; 75:258–63PubMedCrossRef

72.

Santin AD, Bellone S, Parrish RS, et al. Influence of allogeneic blood transfusion on clinical outcome during radiotherapy for cancer of the uterine cervix. Gynecol Obstet Invest 2003; 56:28–34PubMedCrossRef

73.

Dresner SM, Lamb PJ, Shenfine J, Hayes N, Griffin SM. Prognostic significance of peri-operative blood transfusion following radical resection for oesophageal carcinoma. Eur J Surg Oncol 2000; 26:492–7PubMedCrossRef

74.

Busch OR, Hop WC, Hoynck van Papendrecht MA, Marquet RL, Jeekel J. Blood transfusions and prognosis in colorectal cancer. N Engl J Med 1993; 328:1372–6PubMedCrossRef

75.

Busch OR, Hop WC, Marquet RL, Jeekel J. Blood transfusions and local tumor recurrence in colorectal cancer. Evidence of a noncausal relationship. Ann Surg 1994; 220:791–7PubMedCrossRef

76.

Heiss MM, Mempel W, Delanoff C, et al. Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. J Clin Oncol 1994; 12:1859–67PubMed

77.

van de Watering LM, Brand A, Houbiers JG, Klein Kranenbarg WM, Hermans J, van de Velde C. Perioperative blood transfusions, with or without allogeneic leucocytes, relate to survival, not to cancer recurrence. Br J Surg 2001; 88:267–72PubMedCrossRef

78.

Ho J, Sibbald WJ, Chin-Yee IH. Effects of storage on efficacy of red cell transfusion: when is it not safe? Crit Care Med 2003; 31:S687–97PubMedCrossRef

79.

Offner PJ. Age of blood: does it make a difference? Crit Care 2004; 8 (Suppl 2):S24–6PubMedCrossRef

80.

Offner PJ, Moore EE, Biffl WL, Johnson JL, Silliman CC. Increased rate of infection associated with transfusion of old blood after severe injury. Arch Surg 2002; 137:711–6; discussion 716–7PubMedCrossRef

81.

Zallen G, Offner PJ, Moore EE, et al. Age of transfused blood is an independent risk factor for postinjury multiple organ failure. Am J Surg 1999; 178:570–2PubMedCrossRef

82.

Hebert PC, Chin-Yee I, Fergusson D, Blajchman M, Martineau R, Clinch J, Olberg B. A pilot trial evaluating the clinical effects of prolonged storage of red cells. Anesth Analg 2005; 100:1433–8PubMedCrossRef

83.

Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002; 100:2303–20PubMedCrossRef

84.

Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer 2004; 40:2201–16PubMedCrossRef

85.

Rodgers GM 3rd, Cella D, Chanan-Khan A, et al. Cancer- and treatment-related anemia. J Natl Compr Canc Netw 2005; 3:772–89PubMed

86.

Weber RS. A model for predicting transfusion requirements in head and neck surgery. Laryngoscope 1995; 105:1–17PubMedCrossRef

87.

Goodnough LT. Autologous blood donation. Crit Care 2004; 8(Suppl 2):S49–52PubMedCrossRef

88.

Popovsky MA, Whitaker B, Arnold NL. Severe outcomes of allogeneic and autologous blood donation: frequency and characterization. Transfusion 1995; 35:734–7PubMedCrossRef

89.

Tretiak R, Laupacis A, Riviere M, McKerracher K, Souetre E. Cost of allogeneic and autologous blood transfusion in Canada. Canadian Cost of Transfusion Study Group. CMAJ 1996; 154:1501–8PubMed

90.

Bierbaum BE, Callaghan JJ, Galante JO, Rubash HE, Tooms RE, Welch RB. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am 1999; 81:2–10PubMed

91.

Shaheen SP 2nd, Lichtiger B. Autologous deposit of blood by oncology patients: an evaluation of actual use and wastage. Ann Surg Oncol 1995; 2:457–61PubMedCrossRef

92.

Nath A, Pogrel MA. Preoperative autologous blood donation for oral and maxillofacial surgery: an analysis of 913 patients. J Oral Maxillofac Surg 2005; 63:347–9PubMedCrossRef

93.

Jamnicki M, Kocian R, van der Linden P, Zaugg M, Spahn DR. Acute normovolemic hemodilution: physiology, limitations, and clinical use. J Cardiothorac Vasc Anesth 2003; 17:747–54PubMedCrossRef

94.

Segal JB, Blasco-Colmenares E, Norris EJ, Guallar E. Preoperative acute normovolemic hemodilution: a meta-analysis. Transfusion 2004; 44:632–44PubMedCrossRef

95.

Svenmarker S, Engstrom KG. The inflammatory response to recycled pericardial suction blood and the influence of cell-saving. Scand Cardiovasc J 2003; 37:158–64PubMedCrossRef

96.

Andersson I, Tylman M, Bengtson JP, Bengtsson A. Complement split products and pro-inflammatory cytokines in salvaged blood after hip and knee arthroplasty. Can J Anaesth 2001; 48:251–5PubMed

97.

Hansen E, Wolff N, Knuechel R, Ruschoff J, Hofstaedter F, Taeger K. Tumor cells in blood shed from the surgical field. Arch Surg 1995; 130:387–93PubMed

98.

Perseghin P, Vigano M, Rocco G, Della Pona C, Buscemi A, Rizzi A. Effectiveness of leukocyte filters in reducing tumor cell contamination after intraoperative blood salvage in lung cancer patients. Vox Sang 1997; 72:221–4PubMedCrossRef

99.

Gray CL, Amling CL, Polston GR, Powell CR, Kane CJ. Intraoperative cell salvage in radical retropubic prostatectomy. Urology 2001; 58:740–5PubMedCrossRef

100.

Martin RCG, Wellhausen SR, Moehle DA, Martin AW, McMasters KM. Evaluation of intraoperative autotransfusion filtration for hepatectomy and pancreatectomy. Ann Surg Oncol 2005; 12:1017–24PubMedCrossRef

101.

Hansen E, Bechmann V, Altmeppen J. Intraoperative blood salvage in cancer surgery: safe and effective? Transfus Apher Sci 2002; 27:153–7PubMedCrossRef

102.

Freischlag JA. Intraoperative blood salvage in vascular surgery—worth the effort? Crit Care 2004; 8(Suppl 2):S53–6PubMedCrossRef

103.

Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. Second of two parts–blood conservation. N Engl J Med 1999; 340:525–33PubMedCrossRef

104.

PROCRIT® (Epoetin alfa) Prescribing Information. Raritan, NJ: Ortho Biotech Products L.P.; 2007

105.

Scott SN, Boeve TJ, McCulloch TM, Fitzpatrick KA, Karnell LH. The effects of epoetin alfa on transfusion requirements in head and neck cancer patients: a prospective, randomized, placebo-controlled study. Laryngoscope 2002; 112:1221–9PubMedCrossRef

106.

Kosmadakis N, Messaris E, Maris A, Katsaragakis S, Leandros E, Konstadoulakis MM, Androulakis G. Perioperative erythropoietin administration in patients with gastrointestinal tract cancer: prospective randomized double-blind study. Ann Surg 2003; 237:417–21PubMedCrossRef

107.

ARANESP® (Darbepoetin alfa) Prescribing Information. Thousand Oaks, CA: Amgen, Inc.; 2007

108.

EPOGEN® (Epoetin alfa) Prescribing Information. Thousand Oaks, CA: Amgen, Inc.; 2007

109.

Hollender A, Bjoro T, Otto Karlsen K, Kvaloy SO, Nome O, Holte H. Vitamin D deficiency in patients operated on for gastric lymphoma. Scand J Gastroenterol 2006; 41:673–81PubMedCrossRef

110.

Roviello F, Fotia G, Marrelli D, De Stefano A, Macchiarelli R, Pinto E. Iron deficiency anemia after subtotal gastrectomy for gastric cancer. Hepatogastroenterology 2004; 51:1510–4PubMed

111.

Knap MM, Lundbeck F, Overgaard J. Early and late treatment-related morbidity following radical cystectomy. Scand J Urol Nephrol 2004; 38:153–60PubMedCrossRef

112.

Thomas C, Thomas L. Anemia of chronic disease: pathophysiology and laboratory diagnosis. Lab Hematol 2005; 11:14–23PubMedCrossRef

113.

Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004; 22:1301–7PubMedCrossRef

114.

Spahn DR, Kocian R. Artificial O₂ carriers: status in 2005. Curr Pharm Des 2005; 11:4099–114PubMedCrossRef

115.

Goodnough LT, Shander A, Spence R. Bloodless medicine: clinical care without allogeneic blood transfusion. Transfusion 2003; 43:668–76PubMedCrossRef

116.

Jabbour N (ed.). Transfusion-Free Medicine, Surgery. Malden, MA: Blackwell Publishing, Inc.; 2005

117.

Weber RS, Byers RM, Robbins KT, et al. Electrosurgical dissection to reduce blood loss in head and neck surgery. Head Neck 1989; 11:318–24PubMedCrossRef

118.

Shander A, Goodnough LT. Objectives and limitations of bloodless medical care. Curr Opin Hematol 2006; 13:462–70PubMedCrossRef

119.

Levi M. Critical bleeding in surgery: conventional therapy and new prospects. Minerva Anestesiol 2004; 70:267–71PubMed

120.

Kokoszka A, Kuflik P, Bitan F, Casden A, Neuwirth M. Evidence-based review of the role of aprotinin in blood conservation during orthopaedic surgery. J Bone Joint Surg Am 2005; 87:1129–36PubMedCrossRef

121.

Royston D, Chhatwani A. Safety aspects of aprotinin therapy in cardiac surgery patients. Expert Opin Drug Saf 2006; 5:539–52PubMedCrossRef

Title: Anemia and Transfusions in Patients Undergoing Surgery for Cancer
Authors: Randal S. Weber, MD, FACS
Nicolas Jabbour, MD, FACS
Robert C. G. Martin II, MD, FACS
Publication date: 01-01-2008
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 1/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-007-9502-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Anemia and Transfusions in Patients Undergoing Surgery for Cancer

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

Author Reply

Diagnostic Accuracy of Fine Needle Biopsy for Metastatic Melanoma and Its Implications for Patient Management

High-Volume versus Low-Volume for Esophageal Resections for Cancer: The Essential Role of Case-Mix Adjustments based on Clinical Data

Is Routine Use of Sentinel Node Biopsy Justified in Colon Cancer?

Combined [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography (FDG-PET/CT) for Detection of Recurrent, 131I-Negative Thyroid Cancer

Long-Term Results of Liver Resection for Non-colorectal, Non-neuroendocrine Metastases